Related Experiment Video
Updated: Aug 30, 2025
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
The clinical advances of proteolysis targeting chimeras in oncology
Hao Xie1, Junjia Liu2, Diego M Alem Glison1
1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Abstract:
Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for their application in the management of both solid and hematologic malignancies. Since its initial discovery, the technology of targeted protein degradation, especially in the form of PROTACs, has had significant advances. A number of PROTACs have entered a late stage of preclinical development. Several of them are either in phase 1/2 clinical trials or approaching approval for initial clinical evaluation. This article discusses the preclinical and clinical findings of PROTACs of clinically relevant protein targets in cancer.
Insights
Proteolysis targeting chimeras (PROTACs) offer a novel approach to degrade disease-causing proteins. This technology is advancing rapidly, with many PROTACs in clinical trials for cancer treatment.
Area of Science:
- Biochemistry and Molecular Biology
- Oncology
- Pharmacology
Background:
- Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce targeted protein degradation.
- PROTAC technology represents a significant advancement in targeted protein degradation.
- PROTACs hold promise for treating various cancers, including solid and hematologic malignancies.
Purpose of the Study:
- To review the preclinical and clinical progress of PROTACs in cancer therapy.
- To highlight the application of PROTACs against clinically relevant cancer targets.
Main Methods:
- Review of preclinical data for PROTACs targeting cancer proteins.
- Analysis of ongoing and completed clinical trials involving PROTACs.
- Discussion of the mechanism of action and therapeutic potential of PROTACs.
Main Results:
- Numerous PROTACs have demonstrated efficacy in preclinical cancer models.
- Several PROTACs are advancing through Phase 1/2 clinical trials.
- PROTACs are approaching initial clinical evaluation for cancer treatment.
Conclusions:
- PROTACs represent a promising therapeutic strategy for various cancers.
- Continued research and clinical development are essential for realizing the full potential of PROTACs in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy